Hemoglobin A1c (HbA1c) Testing Market 2025

Hemoglobin A1c (HbA1c) Testing Market Definition

Hemoglobin A1c (HbA1c) testing refers to the diagnostic and monitoring tools used to measure the average blood glucose levels over the past two to three months. The test is used to diagnose diabetes, prediabetes, and evaluate the effectiveness of treatment plans in people with diabetes. It is an essential component of diabetes management and is widely used by healthcare providers to assess how well diabetes is being controlled. The HbA1C testing market consists of sales, by entities (organizations, sole traders and partnerships), of HbA1C testing that provides a reliable indication of blood sugar levels by quantifying the percentage of glycosylated hemoglobin in the blood, offering an essential parameter for long-term glucose monitoring. The testing is primarily used by endocrinologists, general practitioners and other healthcare professionals in hospitals, clinics and diagnostic laboratories. Patients themselves may also use these tests in homecare settings for self-monitoring purposes.

Hemoglobin A1c (HbA1c) Testing Market Segmentation

The hemoglobin A1c (HbA1c) testing market is segmented by type, by product type, by technology and by end user. By Type – The hemoglobin A1c (HbA1c) testing market is segmented by type into: a) Laboratory Based Testing b) Point Of Care (PoC) Testing The point of care (PoC) testing market was the largest segment of the hemoglobin A1c (HbA1c) testing market segmented by type, accounting for 78.15% or $1,456.17 million of the total in 2024. Going forward, the point of care (PoC) testing segment is expected to be the fastest growing segment in the hemoglobin A1c (HbA1c) testing market segmented by type, at a CAGR of 9.62% during 2024-2029. By Product Type – The hemoglobin A1c (HbA1c) testing market is segmented by product type into: a) Reagents And Kits b) Instruments c) Software And Services The reagents and kits market was the largest segment of the hemoglobin A1c (HbA1c) testing market segmented by product type, accounting for 61.08% or $1,138.24 million of the total in 2024. Going forward, the software and services segment is expected to be the fastest growing segment in the hemoglobin A1c (HbA1c) testing market segmented by product type, at a CAGR of 11.24% during 2024-2029. By Technology – The hemoglobin A1c (HbA1c) testing market is segmented by technology into: a) Immunoassays b) Chromatography c) Enzymatic Assays d) Boronate Affinity Chromatography e) High Performance Liquid Chromatography f) Other Technologies The immunoassays market was the largest segment of the hemoglobin A1c (HbA1c) testing market segmented by technology, accounting for 36.42% or $678.57 million of the total in 2024. Going forward, the high-performance liquid chromatography segment is expected to be the fastest growing segment in the hemoglobin A1c (HbA1c) testing market segmented by technology, at a CAGR of 12.61% during 2024-2029. By End User – The hemoglobin A1c (HbA1c) testing market is segmented by end user into: a) Hospitals And Clinics b) Diagnostic Laboratories c) Homecare Settings d) Other End Users The hospitals and clinics market was the largest segment of the hemoglobin A1c (HbA1c) testing market segmented by end user, accounting for 40.91% or $762.26 million of the total in 2024. Going forward, the homecare settings segment is expected to be the fastest growing segment in the hemoglobin A1c (HbA1c) testing market segmented by end user, at a CAGR of 13.02% during 2024-2029. By Geography - The hemoglobin A1c (HbA1c) testing market is segmented by geography into: o Asia Pacific • China • India • Japan • Australia • Indonesia • South Korea • Thailand o North America • USA • Canada o South America • Brazil o Western Europe • France • Germany • UK • Italy • Spain o Eastern Europe • Russia o Middle East
o Africa North America was the largest region in the hemoglobin A1c (HbA1c) testing market, accounting for 42.60% or $793.76 million of the total in 2024. It was followed by Asia-Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the hemoglobin A1c (HbA1c) testing market will be Asia-Pacific and South America where growth will be at CAGRs of 10.80% and 10.63% respectively. These will be followed by Middle East and Africa where the markets are expected to grow at CAGRs of 9.83% and 9.54% respectively.

Hemoglobin A1c (HbA1c) Testing Market Drivers

The key drivers of the hemoglobin A1c (HbA1c) testing market include: Strong Economic Growth In Emerging Markets During the forecast period, strong economic growth in emerging markets is expected to support the growth of the hemoglobin A1c (HbA1c) testing market. As emerging economies expand, they generally see an increase in disposable incomes and government revenues, enabling higher healthcare expenditure. As disposable incomes rise in these regions, there is an increased ability to afford healthcare services, which drives higher demand for advanced diagnostic technologies, such as HbA1C testing. Concurrently, governments in these markets are likely to expand healthcare budgets to accommodate the growing demand for medical services, facilitating the adoption of innovative healthcare solutions. For instance, in December 2023, according to the International Monetary Fund (IMF), a US-based international financial institution working to help reduce poverty, encourage trade and promote financial stability and economic growth, Brazil's gross domestic product (GDP) was projected to reach $2.13 trillion in 2023, an increase of 3.1%, which propelled it up to the ninth-largest economy in the world by 2023. Brazil's economy, predicted to be worth $2.476 trillion, could move up one spot to become the eighth largest in the world by 2026. Therefore, strong economic growth in emerging markets is expected to support the growth of the hemoglobin A1c (HbA1c) testing market.

Hemoglobin A1c (HbA1c) Testing Market Restraints

The key restraints on the hemoglobin A1c (HbA1c) testing market include: Lack Of Trained Healthcare Professionals The lack of trained healthcare professionals is expected to restrict the growth of the hemoglobin A1c (HbA1c) testing market going forward. POC HbA1C devices are engineered to deliver rapid and accurate data for diabetes management; however, improper usage can compromise result accuracy. Skilled professionals are essential to operate these devices effectively and adhere to established protocols, ensuring dependable outcomes. For instance, according to the Global Strategy on Human Resources for Health: Workforce 2030 published by the World Health Organization (WHO), there is an anticipated shortfall of 10 million healthcare workers globally by 2030 from 65 million in 2020, mainly in low- and middle-income nations. Additionally, according to the American Hospital Association (AHA), a US-based national organization representing hospitals and health care networks, there will be a shortage of up to 124,000 physicians by 2033, along with a demand for at least 200,000 nurses annually to meet increasing needs. Further, a study anticipates that, based on current workforce trends, over 6.5 million healthcare professionals will exit their roles by 2026, with only 1.9 million replacements anticipated, resulting in a national shortage exceeding 4 million workers. Therefore, the lack of trained healthcare professionals is expected to restrict the growth of the hemoglobin A1c (HbA1c) testing market going forward, in the forecast period.

Hemoglobin A1c (HbA1c) Testing Market Trends

Major trends shaping the hemoglobin A1c (HbA1c) testing market include: Launch Of Next-Generation Point-Of-Care Device Enhances Diabetes Management And Early Diagnosis Companies in the hemoglobin A1c (HbA1c) testing market are focused on developing next-generation point-of-care devices to improve the speed, accuracy, and ease of HbA1c testing, thereby enabling quicker diagnoses and better management of diabetes, ultimately enhancing patient outcomes and reducing healthcare costs. For instance, in July 2024, Siemens Healthineers, a Germany-based healthcare company that specializes in medical technology and diagnostic solutions, launched the Atellica DCA Analyser, a next-generation point-of-care device designed to enhance diabetes management and facilitate early diagnosis. This compact analyser allows clinicians to perform HbA1C and ACR (Albumin-to-Creatinine Ratio) testing directly at the point of care, providing results in just minutes. The Atellica DCA Analyser is particularly beneficial in high-volume clinical settings where quick decision-making is essential. Additionally, in February 2023, Hurdle, a UK-based operator of a diagnostic infrastructure platform, launched an at-home Hemoglobin A1c (HbA1c) test designed for the early detection and monitoring of diabetes in adults. This accessible test allows individuals to measure their average blood glucose levels over the past two to three months from the comfort of their homes, with results typically available within three days. By facilitating timely diagnosis, Hurdle's initiative aims to address the significant number of undiagnosed diabetes cases and empower individuals to take control of their health, ultimately reducing the risk of severe complications associated with the disease. Empowering Health With At-Home Diabetes Risk (HbA1c) Collection Kits Major companies operating in the hemoglobin A1c (HbA1c) testing market are focusing on developing innovative solutions, such as diabetes risk (HbA1c) at-home collection kits, to improve accessibility, enhance early detection of diabetes and empower individuals in managing their long-term glucose levels effectively. Diabetes risk (HbA1c) at-home collection kits refer to diagnostic tools that allow individuals to collect a small blood sample, typically through a finger prick, at home to measure their hemoglobin A1c levels. For instance, in May 2022, Labcorp, a US-based healthcare corporation, launched the Diabetes Risk (HbA1c) at-home collection test, allowing individuals to measure their hemoglobin A1c (HbA1c) levels from a small blood sample using the user-friendly Weavr Velvet blood collection device. This innovative test utilizes dried blood technology and boasts over 97% accuracy compared to traditional blood draws, as supported by research in Clinical Chemistry. This initiative aims to empower consumers to better understand their diabetes risk and manage their health proactively.

Opportunities And Recommendations In The Hemoglobin A1c (HbA1c) Testing Market

Opportunities – The top opportunities in the hemoglobin A1c (HbA1c) testing market segmented by type will arise in the point of care (PoC) testing segment, which will gain $848.40 million of global annual sales by 2029. The top opportunities in the hemoglobin A1c (HbA1c) testing market segmented by product type will arise in the reagents and kits segment, which will gain $661.73 million of global annual sales by 2029. The top opportunities in the hemoglobin A1c (HbA1c) testing market segmented by technology will arise in the immunoassays segment, which will gain $344.40 million of global annual sales by 2029. The top opportunities in the hemoglobin A1c (HbA1c) testing market segmented by end user will arise in the diagnostic laboratories segment, which will gain $403.19 million of global annual sales by 2029. The hemoglobin A1c (HbA1c) testing market size will gain the most in USA at $320.94 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the hemoglobin A1c (HbA1c) testing companies to focus on next-generation point-of-care devices for HbA1c testing, focus on at-home HbA1c testing solutions, focus on high-performance liquid chromatography analyzers for HbA1c testing, focus on enhanced point-of-care testing for HbA1c, focus on point-of-care testing for HbA1c, focus on software and services for HbA1c testing, focus on high performance liquid chromatography for HbA1c testing, focus on software and services for HbA1c testing, expand in emerging markets, continue to focus on developed markets, provide competitively priced offerings, continue to use B2C promotions, participate in trade shows and events, focus on homecare settings for HbA1c testing and focus on targeting urban populations for HbA1c testing.